NEW YORK, NY / ACCESSWIRE / February 19, 2018 / Dr. Joel Singer announces that he plans to fund and start a double-blind study on the use of autologous, adipose derived stem cells for the treatment of osteoarthritis of the knee. The Park Avenue Stem Cell Medical Director also says the study is designed to determine the efficacy of intra-articular autologous adipose derived stem cells in the treatment of osteoarthritis of the human knee. It will be the first prospective, randomized, controlled, double-blind study of this kind.
The safety and efficacy of autologous stem cell treatment
Ever since the discovery by Zuk et al in 2001 of the presence, abundance, and significance of adult pluripotential mesenchymal stem cells as part of the structure and function of human adipose tissue, clinical applications have expanded exponentially all over the world.
There has been ample evidence in peer-reviewed medical literature of the safety of autologous stem cell treatment, including Chang et al in 2013, Centeno et al in 2016, and Berman et al in 2017 comprising more than 3500 patients. Stem cell therapy is considered safe because the stem cells used come from the patient. This minimizes any risk of negative consequences.
Numerous peer-reviewed publications suggest the efficacy of intra-articular injections for osteoarthritis of the knee and other joints in humans. Clinical evidence has been mostly anecdotal but is corroborated by changes in arthroscopy and X-rays.
Researchers believe that when stem cells are injected into an arthritic joint, they develop into cartilage cells, suppress the inflammation that makes the arthritis worse and releases cytokines that slow down cartilage degeneration.
Read more: http://www.digitaljournal.com/pr/3663592#ixzz57eK3Dedz